Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Diabetes mellitus (DM) is a highly prevalent disease worldwide, estimated to affect 1 in every 11 adults; among them, 90–95% of cases are type 2 diabetes mellitus. This is partly attributed to the surge in the prevalence of obesity, which has reached epidemic proportions since 2008. In these patients, cardiovascular (CV) risk stands as the primary cause of morbidity and mortality, placing a substantial burden on healthcare systems due to the potential for macrovascular and microvascular complications. In this context, leptin, an adipocyte-derived hormone, plays a fundamental role. This hormone is essential for regulating the cellular metabolism and energy balance, controlling inflammatory responses, and maintaining CV system homeostasis. Thus, leptin resistance not only contributes to weight gain but may also lead to increased cardiac inflammation, greater fibrosis, hypertension, and impairment of the cardiac metabolism. Understanding the relationship between leptin resistance and CV risk in obese individuals with type 2 DM (T2DM) could improve the management and prevention of this complication. Therefore, in this narrative review, we will discuss the evidence linking leptin with the presence, severity, and/or prognosis of obesity and T2DM regarding CV disease, aiming to shed light on the potential implications for better management and preventive strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961 · cited 1×
“Produced predominantly by subcutaneous white adipose tissue (WAT) rather than visceral adipose tissue [57,58], leptin expression is under the influence of various hormones, including insulin [59] and glucocorticoids [60,61], with an inverse circadian rhythm.”
BackgroundInflammatory mechanisms linking obesity and metabolic disease
Saltiel, A. R., & Olefsky, J. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92035 · Cited by 2,212 · cited 1×
“It is noteworthy that the inflammation triggered by obesity shares many characteristics with inflammation induced by infection, involving both the innate and adaptive immune systems [37,38].”
BackgroundLeptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053 · cited 1×
“In fact, AMPK is pivotal in energy homeostasis and in the majority of diseases associated with metabolic syndrome, such as diabetes, obesity, hypertension, etc., and this is why AMPK-activating drugs reverse many of the metabolic defects associated with insulin resistance [93].”
BackgroundPrevalence of impaired glucose tolerance among children and adolescents with marked obesity
Sinha, R., Fisch, G., Teague, B., Tamborlane, W. V., Banyas, B., Allen, K., Savoye, M., Rieger, V., Taksali, S., Barbetta, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012578 · Cited by 1,709 · cited 1×
“Adolescents with an impaired glucose tolerance (IGT) exhibited greater insulin resistance compared to those with a normal glucose tolerance [31].”
BackgroundFrederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus
Minokoshi, Y., Alquier, T., Furukawa, N., Kim, Y.-B., Lee, A., Xue, B., Mu, J., Foufelle, F., Ferré, P., Birnbaum, M. J., et al. (2004) · Nature · doi:10.1038/nature02440 · Cited by 1,637
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
Neeland, I. J., Ross, R., Després, J.-P., Matsuzawa, Y., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30084-1 · Cited by 1,603 · cited 1×
“This parameter is particularly valuable for individuals classified as normo-or overweight [16].”
BackgroundAhima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Leptin and Obesity: Role and clinical implication.
Obradovic, M., Sudar-Milovanovic, E., Soskic, S., Essack, M., Arya, S., Stewart, A. J., Gojobori, T., & Isenovic, E. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.585887 · Cited by 1,121 · cited 10×
“Several mechanisms within this context are not fully understood, and, in recent years, new strategies have been developed to restore the response to leptin in patients with obesity [12].”
BackgroundInfluentialBlüher, M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa004 · Cited by 1,090
Why does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939 · cited 1×
“Consequently, pancreatic beta cells respond by inadequately secreting insulin in an attempt to overcome this resistance, a phenomenon observed in the early stages of the disease [28,29].”
BackgroundDivergent Signaling Capacities of the Long and Short Isoforms of the Leptin Receptor
Bjørbæk, C., Uotani, S., da Silva, B., & Flier, J. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32686 · Cited by 890
Treatment of Obesity with Celastrol
Liu, J., Lee, J., Salazar Hernandez, M. A., Mazitschek, R., & Ozcan, U. (2015) · Cell · doi:10.1016/j.cell.2015.05.011 · Cited by 726 · cited 1×
“This mechanism is still under study, but it is assumed to be related to the expression of IL-1 receptor 1 in the hypothalamus [147–149].”
BackgroundLeptin in Human Physiology and Pathophysiology
Mantzoros, C. S., Magkos, F., Brinkoetter, M., Sienkiewicz, E., Dardeno, T. A., Kim, S.-Y., Hamnvik, O.-P. R., & Koniaris, A. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2011 · Cited by 593
Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years Later
Izquierdo, A. G., Crujeiras, A. B., Casanueva, F. F., & Carreira, M. C. (2019) · Nutrients · doi:10.3390/nu11112704 · Cited by 525 · cited 2×
“These inhibitors (such as thiazolidinediones and trodusquemine) suppress weight gain and reduce food intake and body weight in mice, as they cross the BBB, making them an interesting option to restore leptin responsiveness [143].”
BackgroundMartin, S. S., Qasim, A., & Reilly, M. P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.060 · Cited by 516 · cited 2×
“Therefore, understanding and regulating leptin levels are of interest in the context of cardiovascular pathology [21].”
BackgroundPharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Roth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436
The “Big Bang” in obese fat: events initiating obesity-induced adipose tissue inflammation
Wensveen, F. M., Valentić, S., Šestan, M., Turk Wensveen, T., & Polić, B. (2015) · European Journal of Immunology · doi:10.1002/eji.201545502 · Cited by 348
Role of Leptin in Inflammation and Vice Versa
Pérez-Pérez, A., Sánchez-Jiménez, F., Vilariño-García, T., & Sánchez-Margalet, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165887 · Cited by 330
Self-citationRole of Selective Leptin Resistance in Diet-Induced Obesity Hypertension
Rahmouni, K., Morgan, D. A., Morgan, G. M., Mark, A. L., & Haynes, W. G. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2012 · Cited by 319 · cited 1×
“In other words, increased plasma leptin levels, either through exogenous leptin administration or ectopic leptin overexpression, elevate blood pressure and heart rate, eventually leading to hypertension [134].”
BackgroundHyperleptinemia Is Required for the Development of Leptin Resistance
Knight, Z. A., Hannan, K. S., Greenberg, M. L., & Friedman, J. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011376 · Cited by 311 · cited 1×
“However, in obese individuals, there is often a condition of hyperleptinemia due to leptin resistance, and, conversely, where leptin resistance is present, it can contribute to elevated leptin levels [66,67].”
BackgroundLeptin and hyperleptinemia - from friend to foe for cardiovascular function
Ren, J. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1810001 · Cited by 305
AMP ‐activated protein kinase: a key regulator of energy balance with many roles in human disease
Grahame Hardie, D. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12268 · Cited by 285
Leptin—Much More Than a Satiety Signal
Harris, R. B. S. (2000) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.20.1.45 · Cited by 222
German, J. P., Thaler, J. P., Wisse, B. E., Oh-I, S., Sarruf, D. A., Matsen, M. E., Fischer, J. D., Taborsky, G. J., Schwartz, M. W., & Morton, G. J. (2011) · Endocrinology · doi:10.1210/en.2010-0890 · Cited by 169 · cited 2×
“It is worth noting that certain antidiabetic drugs, including metformin, pioglitazone, sitagliptin, liraglutide, and empagliflozin, have been shown to reduce leptin levels, although the clinical implications of these drugs’ effect have not yet been fully elucidated [110,112].”
BackgroundSelective leptin resistance revisited
Mark, A. L. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00180.2013 · Cited by 162 · cited 1×
“Leptin resistance may arise from various factors, including alterations in leptin expression, mutations in leptin or its receptors, or disruptions in leptin transport across the blood–brain barrier (BBB) [101–105].”
BackgroundBombelli, M., Facchetti, R., Sega, R., Carugo, S., Fodri, D., Brambilla, G., Giannattasio, C., Grassi, G., & Mancia, G. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.175125 · Cited by 126 · cited 1×
“For every 1 kg/m 2 increase in BMI, the risk of LV hypertrophy increases by 5.1%, and, for every 1 cm increase in waist circumference, the risk of LV hypertrophy increases by 2.6% [19].”
BackgroundInfluentialMyocardial infarction and heart failure in the db/db diabetic mouse
Greer, J. J. M., Ware, D. P., & Lefer, D. J. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00583.2005 · Cited by 108 · cited 1×
“In animal models of obesity with mutations in the ob gene or LepR, heart failure was commonly observed [113,114].”
Background
Metadata
- Authors
- Vilariño-García, T., Polonio-González, M., Pérez-Pérez, A., Ribalta, J., Arrieta, F., Aguilar, M., Obaya, J., Gimeno-Orna, J., Iglesias, P., Navarro, J., Durán, S., Pedro-Botet, J., & Sánchez-Margalet, V.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-02-16
- Volume
- 25
- Issue
- 4
- Pages
- 2338
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4391883674
- Cited by
- 170
- References
- 30
- FWCI
- 44.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.